Skip to content
thispeptide

How Much Weight Can You Lose on Semaglutide? What the STEP Trials Measured

Adults without diabetes lost about 15% of body weight over 68 weeks on 2.4 mg, and half lost 15% or more. People with diabetes lost less, the 7.2 mg dose added about 3 points, and most of the loss returned within a year of stopping.

Article type
Evidence
Evidence on Semaglutide for weight
Large trials1 randomized trial of 1,000 or more people cited here for weight.
Sources
7
Reading
7 min
By Leah GarnerPublished

The trials give a fairly consistent answer: about 15% of body weight on the 2.4 mg dose, for adults with obesity and without diabetes, reached over a year or more. The spread around that average is wide, and people with diabetes lost less.

This page sets out what the semaglutide weight trials measured: the average, the spread, the effect of diabetes and dose, and how long the loss lasted.

What STEP 1 measured

STEP 1 randomized 1,961 adults with a BMI of 30 or more, or 27 or more with a weight-related condition [2]. People with diabetes were excluded. Two in three got semaglutide 2.4 mg once weekly and one in three got placebo, for 68 weeks, with lifestyle counseling for everyone.

−14.9%

Mean weight change on 2.4 mg at week 68

Wilding 2021

−2.4%

Mean weight change on placebo

Wilding 2021

−15.3 kg

Mean change on 2.4 mg, against −2.6 kg on placebo

Wilding 2021

The 15.3 kg average is about 34 pounds. That conversion is plain arithmetic on the trial’s own figure, not a number the trial reported in pounds.

The analysis counted everyone assigned to the drug, including people who stopped taking it. So the average includes some who were no longer on treatment by week 68.

How the results were spread

A single mean says little about one person. STEP 1 also reported the share of each group that crossed each threshold at week 68 [2].

Share of STEP 1 participants reaching each weight-loss level at week 68
Weight lostPlaceboSemaglutide 2.4 mg
5% or more31.5%86.4%
10% or more12.0%69.1%
15% or more4.9%50.5%
Share of STEP 1 participants reaching each weight-loss level at week 68

Read the other way, about 14% of the semaglutide group did not reach a 5% loss. About half did not reach 15%. Gastrointestinal effects led 4.5% on semaglutide to stop treatment, against 0.8% on placebo.

The full side-effect record is in semaglutide side effects.

With type 2 diabetes

STEP 2 enrolled 1,210 adults with type 2 diabetes and a BMI of 27 or more [3]. After 68 weeks, weight fell 9.6% on 2.4 mg and 3.4% on placebo.

That is a real loss, but about 5 points less than in STEP 1. The same gap between people with and without diabetes appears in the tirzepatide trials, set out in how much weight you can lose on tirzepatide.

How fast it comes off

The label starts at 0.25 mg weekly and steps up every 4 weeks, reaching 2.4 mg at week 17 [1]. Much of the first four months is spent on doses below the one the trials tested for weight.

The dose steps are covered in semaglutide dosage, and the early weeks in how long semaglutide takes to work.

Two years and four years

STEP 5 ran for 104 weeks in 304 adults without diabetes [4]. Weight fell 15.2% on 2.4 mg and 2.6% on placebo, and 77.1% on semaglutide kept at least a 5% loss at two years.

The SELECT trial followed 17,604 adults with heart disease and overweight or obesity, without diabetes [5]. Its weight analysis found the loss continued for 65 weeks and held to week 208.

At 208 weeks the mean change was 10.2% on semaglutide and 1.5% on placebo. SELECT was a heart-outcomes trial in an older, higher-risk group, so its weight figure is not directly comparable with STEP 1.

What the 7.2 mg dose added

The label now allows 7.2 mg weekly for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight reduction [1]. STEP UP tested it in 1,407 adults with obesity and without diabetes [6].

At 72 weeks, mean weight change was 18.7% on 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo. The extra 3.1 points came with more side effects.

Gastrointestinal effects were reported by 70.8% on 7.2 mg and 61.2% on 2.4 mg. Dysesthesia, an altered or painful skin sensation, affected 22.9% on 7.2 mg against 6.0% on 2.4 mg.

Stopping is covered in more depth in what happens when you stop taking semaglutide.

What these numbers do not tell you

Every trial here used the brand injection alongside diet and activity counseling. Most participants were women: 77.6% in STEP 5 and 73.7% in STEP UP [4] [6].

No trial here tested compounded semaglutide, so these figures say nothing either way about it. The daily alternative produced smaller losses, as set out in liraglutide dosage. For eating on the drug, see what to eat on semaglutide.

The tablet form has its own trial record, covered in Wegovy pill. To compare online prescribers, see the compounded semaglutide rankings and the broader weight-loss peptide rankings.

Frequently asked questions

How much weight do people lose on semaglutide?
In STEP 1, adults with obesity and without diabetes lost an average of 14.9% of body weight over 68 weeks on 2.4 mg weekly, against 2.4% on placebo. About half lost 15% or more.
Do people with diabetes lose as much weight on semaglutide?
Less. In STEP 2, adults with type 2 diabetes lost 9.6% on 2.4 mg over 68 weeks, against 3.4% on placebo.
Does the 7.2 mg dose of semaglutide cause more weight loss?
In STEP UP, mean weight change at 72 weeks was 18.7% on 7.2 mg and 15.6% on 2.4 mg. Gastrointestinal effects and dysesthesia were more common on the higher dose.
Does the weight stay off after stopping semaglutide?
In the STEP 1 extension, people who stopped after 68 weeks regained 11.6 percentage points of their 17.3% loss by week 120, leaving a net loss of 5.6%.

Sources

7 cited
  1. 1DailyMed, U.S. National Library of Medicine (2026). WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets: prescribing information (revised 06/2026) DailyMed. Source
  2. 2Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. PMID 33567185
  3. 3Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet. PMID 33667417
  4. 4Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nature Medicine. PMID 36216945
  5. 5Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature Medicine. PMID 38740993
  6. 6Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial Lancet Diabetes & Endocrinology. PMID 40961952
  7. 7Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism. PMID 35441470

Where to get it

Best compounded semaglutide prescribers

Sellers of semaglutide.

Compare providers →

More on weight